Positron emission tomography (PET) is an established tool for molecular imaging of cancers, and its role in diagnosis, staging, and phenotyping continues to evolve and expand rapidly. PET imaging of increased glucose utilization with 18F-fluorodeoxyglucose is now entrenched in clinical oncology practice for improving prognostication and treatment response assessment. Additional critical processes for cancer cell survival can also be imaged by PET, helping to inform individualized treatment selections for patients by improving our understanding of cell survival mechanisms and identifying relevant active mechanisms in each patient. The critical importance of quantifying cell proliferation and DNA repair pathways for prognosis and treatment selection is highlighted by the nearly ubiquitous use of the Ki-67 index, an established histological quantitative measure of cell proliferation, and BRCA mutation testing for treatment selection. This review focuses on PET advances in imaging and quantifying cell proliferation and poly(ADP-ribose)polymerase expression that can be used to complement cancer phenotyping approaches that will identify the most effective treatments for each individual patient.
Keyphrases
- positron emission tomography
- pet imaging
- computed tomography
- dna repair
- pet ct
- cell proliferation
- dna damage
- high resolution
- end stage renal disease
- healthcare
- chronic kidney disease
- metabolic syndrome
- adipose tissue
- poor prognosis
- primary care
- case report
- cell cycle
- type diabetes
- palliative care
- ejection fraction
- prognostic factors
- skeletal muscle
- blood glucose
- photodynamic therapy
- blood pressure
- lymph node
- smoking cessation
- binding protein